Mangafodipir treatment for oxaliplatin-associated neuropathy

An unfortunate side effect of the platinum-chemotherapy drug oxaliplatin is the development of neurotoxicity, which can adversely affect a patient's quality of life; therefore, the benefit of oxaliplatin-based therapy must be balanced with prevention of neuropathies. Currently, there are no therapeutic interventions available to relieve oxaliplatin-associated neurological symptoms, which are thought to be a result of reactive oxygen species-associated damage.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Related Links:

CONCLUSION: In this group of GPs, participation rates were high for most of the therapeutic and communicative tasks suggested in the questionnaire. GP participation is feasible not only in palliative care, but also in some aspects of oncological treatment and in clinical follow-up. Communication with both patient and hospital seemed good in this local setting. GPs are important helpers for some cancer patients. PMID: 29788744 [PubMed - in process]
Source: Rural and Remote Health - Category: Rural Health Tags: Rural Remote Health Source Type: research
This article will review relevant literature concerning current surgical techniques for resection of centrally located NSCLC using thoracotomy and will emphasize the benefits and challenges of a video-assisted thoracic surgery (VATS) approach. PMID: 29791705 [PubMed - in process]
Source: Surgical Technology International - Category: Surgery Tags: Surg Technol Int Source Type: research
CONCLUSION: Combined regimen of chemotherapy in locally advanced cervical cancer proved to be valuable and efficacious without any late complications. PMID: 29787015 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSIONS: A significant proportion of patients with epithelial ovarian cancer treated with carboplatin plus paclitaxel suffer long term neuropathy and it affects patient's daily activities. Specialized care is necessary to provide not only during treatment, but also months to years after drugs withdrawal. PMID: 29787013 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSION: LESS is feasible, safe, and is an alternative minimally invasive procedure to assess the resectability of AOC patients. PMID: 29787008 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSION: Patients with classic variant of infiltrate lobular cancer of breast should be regularly follow-up, which could permit early diagnosis of distant metastases and improve treatment results. PMID: 29787007 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSIONS: Adjuvant concomitant CR is well tolerated and is a feasible regimen in "high risk" patients. The authors' new algorithm treatment could be used for management and further clinical studies. PMID: 29787005 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
CONCLUSIONS: SCR HIPEC compared with CTA improves PFI-2 in patients with platinum-sensitive EOC recurrence. SCR + HIPEC might also improve OS in comparison with CTA. No improvement in favor of SCR + HIPEC vs SCR was observed,. These results further support the need of a randomized trial comparing chemotherapy with SCR ± HIPEC in this setting. PMID: 29787001 [PubMed - in process]
Source: European Journal of Gynaecological Oncology - Category: OBGYN Tags: Eur J Gynaecol Oncol Source Type: research
Condition:   Esophageal Cancer Interventions:   Radiation: standard chemoradiotherapy;   Radiation: experimental chemoradiotherapy Sponsor:   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Stage IV Breast Cancer AJCC v6 and v7 Interventions:   Dietary Supplement: Dietary Intervention;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration Sponsor:   Ohio State University Comprehensive Cancer Center Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Eloxatin | Health | Neurology